Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC
Complete. Here is the key summaryH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Kura Oncology with an unchanged $40 price target, citing encouraging Phase 1a data for darlifarnib combined with cabozantinib in advanced renal cell carcinoma. The combination showed up to 50% response rates and manageable safety. Bank of America Securities also maintained a Buy rating with a $30 target.
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology. The associated price target remains the same with $40.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily the encouraging clinical profile of darlifarnib in combination with cabozantinib in advanced, cabo-naïve clear cell renal cell carcinoma. The Phase 1a FIT-001 data show response rates of up to 50% and a median progression-free survival of around 13 months in a heavily pretreated population, with safety that remains manageable even at full-dose cabozantinib.
Pantginis also views darlifarnib’s ability to potentially boost the effectiveness of widely used VEGF tyrosine kinase inhibitors as a key strategic asset that could position it as a backbone in targeted therapy regimens. With a global randomized Phase 1b study underway and a broader platform strategy to test darli across multiple targeted combinations, he sees a clear pathway for value creation and thus maintains a $40 price target, unchanged from prior estimates.
In another report released on July 22, Bank of America Securities also maintained a Buy rating on the stock with a $30.00 price target.